KYT Dental Services
Denosumab · Dental implants

Denosumab and dental implant healing

Quick answer

Dental implants in patients on Prolia for osteoporosis generally have success rates close to non-users in the short and medium term. The MRONJ concern is real but low. Cancer-dose denosumab (Xgeva) is a different conversation because the MRONJ risk is substantially higher. Most patients on Prolia can get implants with appropriate planning, including timing around the dose schedule and close post-surgical follow-up.

The mechanism
Why denosumab affects implant placement differently than bisphosphonates

Dental implant success depends on osseointegration: bone growing into the surface of the titanium implant. This process requires active bone remodeling. Denosumab slows that remodeling by blocking RANK ligand, which is the signal that activates osteoclasts. The intuition is that denosumab would impair osseointegration, but studies of Prolia patients show implant survival rates similar to non-users in the short and medium term.

The bigger concern, as with bisphosphonates, is MRONJ at the surgical site. Implant placement involves osteotomy (drilling into the jaw bone), which is meaningful surgical trauma. In patients on cancer-dose denosumab (Xgeva), the MRONJ risk after this kind of surgery is high enough that implants are usually considered case by case. In patients on osteoporosis-dose denosumab (Prolia), the risk is lower and implants are more commonly placed.

Timing matters more for denosumab than for bisphosphonates because the drug effect reverses within months of stopping. Some practitioners time implant placement to occur near the end of a Prolia dose cycle (typically a 6-month interval), when bone turnover has partially recovered. This is a personal preference more than a guideline, but it is a reasonable approach.

Practical steps
What to do if you are on denosumab and considering implants
  • Tell your dentist whether you are on Prolia (osteoporosis dose, every 6 months) or Xgeva (cancer dose, more frequent). The conversation is different.
  • Tell us when your last injection was and when the next is scheduled.
  • Coordinate with your prescribing physician. They can confirm your underlying condition and discuss timing.
  • Optimize oral hygiene before surgery. Local bacterial load matters for MRONJ risk.
  • Plan for slightly more conservative surgical technique. Atraumatic flap design and careful socket preservation matter more in patients on anti-resorptive medications.
  • Schedule longer follow-up. Implant sites in denosumab patients are watched carefully in the first six months.
Red flags
When to call your dentist after implant surgery
  • An area of exposed bone in the mouth, even if not painful.
  • Pain that gets worse after day three instead of better.
  • Swelling or pus from the surgical site.
  • The implant feels loose or wobbly at any point.
  • A non-healing socket or surgical site weeks after the procedure.
Common questions
What patients ask about Denosumab (Prolia) and dental implant healing.
Can I get a dental implant on Prolia?
Usually yes, with appropriate planning. Studies show implant survival rates close to non-users in patients on osteoporosis-dose denosumab. The conversation includes how long you have been on Prolia, when the next dose is scheduled, and your other dental risk factors.
Is denosumab safer than alendronate for implants?
Similar implant success rates in studies. The main practical difference is that denosumab effects reverse within months of stopping, while bisphosphonates persist in bone for years. This makes timing more flexible with denosumab. The MRONJ profile is otherwise comparable for the osteoporosis doses.
Should I time my implant around my Prolia injection?
Possibly. Some practitioners place implants in the last few weeks before the next scheduled Prolia dose, when bone turnover has partially recovered. Others continue the dose schedule and rely on careful technique. There is no single right answer; the decision is case by case.
What is the implant failure rate on denosumab?
For osteoporosis-dose denosumab, studies show short and medium-term implant survival rates close to the general population. Long-term data is still accumulating. For cancer-dose denosumab (Xgeva), implants are much more cautious territory with higher complication rates.
Can MRONJ develop years after an implant on denosumab?
Yes, in principle, especially if you continue denosumab long-term and have other surgical work around the implant later. MRONJ does not have a clean expiration window. Patients on long-term denosumab should keep their dentist informed at every visit, and any subsequent extractions or surgical work near existing implants should be planned with this history in mind.
Talk to a dentist about your case
Bring your medication list to your visit.

General guidance is a starting point. Your specific dental plan depends on your medical history, your other medications, and what your mouth looks like in person. Schedule a consultation and we’ll walk through it.

Schedule a consultationCall (833) 598-3368

Reviewed by Dr. Isaac Sun, DDS.

This page is general information, not medical advice. Do not start, stop, or change any medication based on what you read here. Talk to your prescribing physician and your dentist about your specific situation.